Search Videos and More

Showing 1 - 12 of 22 results

Previous| 1 | 2 |Next


High-Dose Vitamin D3 Does Not Provide Benefit for Metastatic Colorectal Cancer News

High-Dose Vitamin D3 Does Not Provide Benefit for Metastatic Colorectal Cancer

SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial of vitamin D combined with standard chemotherapy plus bevacizumab in patients with previously untreated metastatic colorectal cancer.
Early Action, Better Outcomes: Transforming Cancer Prevention News

Early Action, Better Outcomes: Transforming Cancer Prevention

For more than 100 years, health advocates have spread the message that, with cancer, patience is not a virtue.
In a First, Immune Checkpoint Inhibitors Show Effectiveness in Metastatic Colorectal Cancer News

In a First, Immune Checkpoint Inhibitors Show Effectiveness in Metastatic Colorectal Cancer

In trial after clinical trial, metastatic colorectal cancer has been largely undeterred by immune checkpoint inhibitors. 
Live Cell Imaging IDs Bad Actors in Cancer and Finds Possible Ways to Defeat Them News

Live Cell Imaging IDs Bad Actors in Cancer and Finds Possible Ways to Defeat Them

Most forms of chemotherapy are designed to kill cancer cells. But some cancer cells survive. Those that do can cause the cancer to relapse.
New Targeted Treatments Emerge for Gastric and Esophageal Cancer News

New Targeted Treatments Emerge for Gastric and Esophageal Cancer

For years, patients with advanced forms of gastric and esophageal cancer have had relatively few treatment options.
New Research from Dana-Farber Brigham Cancer Center and Memorial Sloan Kettering Cancer Center Finds that Radiation Can Be Safely Omitted in Select Patients with Locally Advanced Rectal Cancer News

New Research from Dana-Farber Brigham Cancer Center and Memorial Sloan Kettering Cancer Center Finds that Radiation Can Be Safely Omitted in Select Patients with Locally Advanced Rectal Cancer

New data led by researchers at Dana-Farber Brigham Cancer Center and Memorial Sloan Kettering Cancer Center (MSK) and featured in the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting press program and simultaneously published in?The New England Journal of Medicine (NEJM)?and the Journal of Clinical Oncology today indicates that some patients with locally advanced rectal cancer with tumors that respond to chemotherapy can safely forego radiation before surgery.
Clinical Trial Shows That Adding Bevacizumab to Targeted Drug and Chemotherapy Produces Striking Activity Against HER2-Positive Metastatic Gastroesophageal Adenocarcinoma News

Clinical Trial Shows That Adding Bevacizumab to Targeted Drug and Chemotherapy Produces Striking Activity Against HER2-Positive Metastatic Gastroesophageal Adenocarcinoma

Long-term results and ctDNA correlatives for CAPOX BETR: A multi-center phase II trial of capecitabine, oxaliplatin, bevacizumab and trastuzumab for previously untreated HER2 positive metastatic gastroesophageal adenocarcinoma
A Common Cancer at an Uncommon Age News

A Common Cancer at an Uncommon Age

Colorectal cancer among young people is increasing globally and rapidly. Experts expect it to become the leading cause of cancer death in individuals aged 20-49 in the U.S. by the year 2030.
Studies of Novel Therapeutic Approaches Highlighted During Colorectal Cancer Awareness Month at Dana-Farber News

Studies of Novel Therapeutic Approaches Highlighted During Colorectal Cancer Awareness Month at Dana-Farber

Colorectal cancer is the 3rd most common cancer among men and women of all ages in the US and is on track to be the leading cause of cancer death in adults under 50 by 2030.
Immunotherapy With Two Novel Drugs Shows Activity in Colorectal Cancer News

Immunotherapy With Two Novel Drugs Shows Activity in Colorectal Cancer

A combination of two next-generation immunotherapy drugs has shown promising clinical activity in treating patients with refractory metastatic colorectal cancer, a disease which has not previously responded well to immunotherapies, according to a Dana-Farber Cancer Institute researcher.
Online Testing Tool Identifies People Likely to Benefit from Genetic Testing for Inherited Risk for Certain Cancers News

Online Testing Tool Identifies People Likely to Benefit from Genetic Testing for Inherited Risk for Certain Cancers

An online tool developed by researchers and physicians at Dana-Farber Cancer Institute can accurately and rapidly identify people who should undergo testing for inherited genetic changes that raise the risk of developing certain cancers, a new study shows.
Young-Onset Colorectal Cancer Center Gut Instincts Series: Best Practices for Symptom Management Video

Young-Onset Colorectal Cancer Center Gut Instincts Series: Best Practices for Symptom Management

Dana-Farber’s Young-Onset Colorectal Cancer Center's Gut Instincts series continued on Tuesday, January 25 with an educational workshop on Best Practices for Symptom Management.

Showing 1 - 12 of 22 results

Previous| 1 | 2 |Next